Clinical Trials Directory

Trials / Completed

CompletedNCT03723200

Analyzes of Hemorrhagic Obstetric Patients Whose Were Used Fibrinogen

Treatment of Obstetric Hemorrhage With Fibrinogen and Blood Products: Retrospective Analyzes

Status
Completed
Phase
Study type
Observational
Enrollment
56 (actual)
Sponsor
Kanuni Sultan Suleyman Training and Research Hospital · Academic / Other
Sex
Female
Age
18 Years – 50 Years
Healthy volunteers

Summary

The files of hemorrhagic obstetric patients undergoing surgery and followed in the intensive care unit and using Fibrinogen and blood products were included in the study between January 2015- September 2018 at the Anesthesiology and Reanimation Clinic of SBU Kanuni Sultan Süleyman Training and Research Hospital. Patients under 18 years of age were excluded from the study. In this study, ages, operation types, number of blood and products, the amount of fibrinogen, the results of the hemogram and bleeding parameters, the levels of fibrinogen, the duration of hospital stay and the intensive care unit were recorded.

Detailed description

Bleeding is an important event that threatens the patient's life. Too much blood and blood products can be used in massive bleeding. However, unwanted allergic reactions may occur in blood and blood product transfusions. Fibrinogen is the first coagulation factor in coagulopathy. Some studies have shown that when the fibrinogen level falls to \<150-200 mg / dl, the bleeding increases dramatically.

Conditions

Interventions

TypeNameDescription
OTHERFibrinogen and blood productsFibrinogen and blood products

Timeline

Start date
2018-10-09
Primary completion
2018-10-16
Completion
2018-10-24
First posted
2018-10-29
Last updated
2018-10-30

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT03723200. Inclusion in this directory is not an endorsement.